KR20040099291A - 종양 치료용 자가이식성 백신의 제조를 위한 긴 펜트락신ｐｔｘ３ 작용성 유도체 - Google Patents

종양 치료용 자가이식성 백신의 제조를 위한 긴 펜트락신ｐｔｘ３ 작용성 유도체 Download PDF

Info

Publication number
KR20040099291A
KR20040099291A KR10-2004-7013464A KR20047013464A KR20040099291A KR 20040099291 A KR20040099291 A KR 20040099291A KR 20047013464 A KR20047013464 A KR 20047013464A KR 20040099291 A KR20040099291 A KR 20040099291A
Authority
KR
South Korea
Prior art keywords
leu
ptx3
ala
gly
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR10-2004-7013464A
Other languages
English (en)
Korean (ko)
Inventor
리타 데산티스
기오반니 살바토리
Original Assignee
시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이. filed Critical 시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이.
Publication of KR20040099291A publication Critical patent/KR20040099291A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR10-2004-7013464A 2002-02-28 2003-02-25 종양 치료용 자가이식성 백신의 제조를 위한 긴 펜트락신ｐｔｘ３ 작용성 유도체 Ceased KR20040099291A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT2002RM000109A ITRM20020109A1 (it) 2002-02-28 2002-02-28 Derivati funzionali della pentraxina lunga ptx3 per preparare un vaccino autologo per la cura dei tumori.
ITRM2002A000109 2002-02-28
PCT/IT2003/000104 WO2003072603A2 (en) 2002-02-28 2003-02-25 Long pentraxin ptx3 functional derivatives for preparing an autologous vaccine for the treatment of tumours

Publications (1)

Publication Number Publication Date
KR20040099291A true KR20040099291A (ko) 2004-11-26

Family

ID=11456119

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2004-7013464A Ceased KR20040099291A (ko) 2002-02-28 2003-02-25 종양 치료용 자가이식성 백신의 제조를 위한 긴 펜트락신ｐｔｘ３ 작용성 유도체

Country Status (12)

Country Link
US (1) US20090110666A1 (enExample)
EP (1) EP1478661A2 (enExample)
JP (1) JP2005538690A (enExample)
KR (1) KR20040099291A (enExample)
AR (1) AR038854A1 (enExample)
AU (1) AU2003214645A1 (enExample)
CA (1) CA2475526A1 (enExample)
IT (1) ITRM20020109A1 (enExample)
MX (1) MXPA04008217A (enExample)
PL (1) PL372719A1 (enExample)
TW (1) TWI293958B (enExample)
WO (1) WO2003072603A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20040858A1 (it) 2004-04-29 2004-07-29 Farma Dev S R L Anticorpi monoclonali ibridomi metodo migliorato per determinare la proteina ptx3 e kit per detta determinazione
ITRM20040489A1 (it) * 2004-10-08 2005-01-08 Sigma Tau Ind Farmaceuti Pentraxina lunga ptx3 deglicosilata o desialidata.
SI1973944T1 (sl) * 2006-01-24 2016-07-29 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. FGF2 vezavni peptidi in njihova uporaba
US9226960B2 (en) 2010-04-16 2016-01-05 Andrew B. Bush FGF modulation of in vivo antibody production and humoral immunity
US8435525B1 (en) * 2010-04-16 2013-05-07 Andrew B. Bush FGF modulation of in vivo antibody production and humoral immunity
TWI531375B (zh) 2015-05-29 2016-05-01 國立成功大學 抑制癌細胞活性之短肽治療劑及含此之醫藥組成物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849478A (en) * 1986-08-14 1998-12-15 Cashman; Daniel P. Blocked-polymerase polynucleotide immunoassay method and kit
US5290551A (en) * 1990-05-08 1994-03-01 Thomas Jefferson University Treatment of melanoma with a vaccine comprising irradiated autologous melanoma tumor cells conjugated to a hapten
IT1298487B1 (it) * 1997-12-19 2000-01-10 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale,
IT1317927B1 (it) * 2000-11-03 2003-07-15 Sigma Tau Ind Farmaceuti Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patologie autoimmuni.
IT1317930B1 (it) * 2000-11-08 2003-07-15 Sigma Tau Ind Farmaceuti Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patalogie associate ad una alterata attivazione
US20020122820A1 (en) * 2001-01-16 2002-09-05 Hildebrand William H. Soluble MHC artificial antigen presenting cells
AU2002324328B2 (en) * 2001-08-03 2007-09-06 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of long pentraxin PTX3 for treating female infertility
US7041648B2 (en) * 2001-08-03 2006-05-09 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Compositions and methods for treating female fertility
ITRM20020191A1 (it) * 2002-04-08 2003-10-08 Sigma Tau Ind Farmaceuti Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patologie tumorali associate ad una alterata att
US20040137544A1 (en) * 2002-10-31 2004-07-15 Roberto Latini PTX3 as an early prognostic indicator of cardiovascular and cerebrovascular pathologies
ITRM20030596A1 (it) * 2003-12-23 2005-06-24 Sigma Tau Ind Farmaceuti Uso di inibitori della pentraxina lunga ptx3, per la preparazione di un medicamento per la prevenzione e cura di patologie che rispondono all'inibizione dell'attivita' biologica di detta ptx3.
US20070023879A1 (en) * 2005-07-29 2007-02-01 Vinayak Pandey Single unit heat sink, voltage regulator, and package solution for an integrated circuit

Also Published As

Publication number Publication date
TW200303755A (en) 2003-09-16
EP1478661A2 (en) 2004-11-24
WO2003072603A2 (en) 2003-09-04
PL372719A1 (en) 2005-07-25
CA2475526A1 (en) 2003-09-04
WO2003072603A3 (en) 2004-03-18
US20090110666A1 (en) 2009-04-30
AR038854A1 (es) 2005-01-26
MXPA04008217A (es) 2004-11-26
WO2003072603A9 (en) 2004-10-07
AU2003214645A1 (en) 2003-09-09
AU2003214645A8 (en) 2003-09-09
ITRM20020109A0 (it) 2002-02-28
ITRM20020109A1 (it) 2003-08-28
TWI293958B (en) 2008-03-01
JP2005538690A (ja) 2005-12-22

Similar Documents

Publication Publication Date Title
KR102653758B1 (ko) 인터류킨-2/인터류킨-2 수용체 알파 융합 단백질 및 사용 방법
TWI228128B (en) Tumor antigenic peptides derived from cyclophilin B
US7390871B2 (en) Tumor antigen based on products of the tumor suppressor gene WT1
AU2019212840B2 (en) Expression of metabolic modulators in tumor microenvironment to improve tumor therapy
KR19980703453A (ko) 악성 종양의 예방 또는 치료용의 ＨＥＲ-２/ｎｅｕ 단백질의세포내 도메인
KR100560085B1 (ko) 긴 펜트락신 ｐｔｘ3를 포함하는 약제학적 조성물
CA2257531A1 (en) Tumor antigen proteins, genes thereof, and tumor antigen peptides
ES2316191T3 (es) Nueva proteina antigenica tumoral sart-3 y peptido antigenico tumoral de la misma.
KR20040099291A (ko) 종양 치료용 자가이식성 백신의 제조를 위한 긴 펜트락신ｐｔｘ３ 작용성 유도체
US7071294B1 (en) Tumor antigen protein art-1 and tumor antigen peptide thereof
EP1103561B1 (en) Hla-a2 restraint tumor antigen peptide originating in sart-1
CA2247799A1 (en) Polynucleotides and polypeptides belonging to the uncoupling proteins family
CA2316396A1 (en) Tumor antigen protein, gene thereof, and utilization thereof
KR100465546B1 (ko) 종양항원단백질,그의유전자및종양항원펩티드
JP2000116383A (ja) ヒト癌退縮抗原タンパク質
CN120098146A (zh) 一种高亲和力融合蛋白、核酸分子、药物组合物及其用途
WO1999021986A1 (en) Cbfbga09: a human sl15 homolog
CA2332568A1 (en) Tumor antigen peptide originating in sart-1
HK1036996A (en) Hla-a2 restraint tumor antigen peptide originating in sart-1
JPWO2000006595A1 (ja) Ｓａｒｔ−１由来のｈｌａ−ａ２拘束性腫瘍抗原ペプチド
CN1276010A (zh) Cbfbga09∶人sl15同源物

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20040827

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20071224

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20091127

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20100203

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20091127

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I